Edinburgh-based biotechnology company developing patented msX™ nucleic-acid-binding polymers and cfDNA extraction products for liquid biopsy
Edinburgh-based biotechnology company developing patented msX™ nucleic-acid-binding polymers and cfDNA extraction products for liquid biopsy. Its technology selectively captures cell-free DNA from biological fluids, including whole blood, without additional binding reagents or centrifugation, supporting cancer diagnostics, genetic testing, precision medicine, and multi-omics research.